See more : Unistar Multimedia Limited (UNISTRMU.BO) Income Statement Analysis – Financial Results
Complete financial analysis of NLS Pharmaceutics AG (NLSP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NLS Pharmaceutics AG, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Nichols plc (NJMVF) Income Statement Analysis – Financial Results
- Raiffeisen Bank International AG (RAW.DE) Income Statement Analysis – Financial Results
- Indara Insurance Public Company Limited (INSURE.BK) Income Statement Analysis – Financial Results
- MedAdvisor Limited (MDR.AX) Income Statement Analysis – Financial Results
- Yaari Digital Integrated Services Limited (YAARI.BO) Income Statement Analysis – Financial Results
NLS Pharmaceutics AG (NLSP)
About NLS Pharmaceutics AG
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 11.41K | 11.41K | 10.05K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -11.41K | -11.41K | -10.05K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.91M | 8.98M | 5.92M | 99.58K | 1.70M | 1.44M | 4.32M |
| General & Administrative | 5.90M | 6.51K | 5.94K | 2.20K | 3.30M | 2.01M | 1.44M |
| Selling & Marketing | 0.00 | 6.49M | 5.93M | 2.20M | 2.49M | 0.00 | 0.00 |
| SG&A | 5.90M | 6.49M | 5.93M | 2.20M | 2.49M | 2.01M | 1.44M |
| Other Expenses | 0.00 | 10.05K | -17.32K | -328.37K | 0.00 | -629.23K | 0.00 |
| Operating Expenses | 11.81M | 15.47M | 11.85M | 2.30M | 4.20M | 3.45M | 5.77M |
| Cost & Expenses | 11.81M | 15.48M | 11.86M | 2.30M | 4.20M | 3.45M | 5.77M |
| Interest Income | 0.00 | 100.87 | 68.13 | 233.70 | 819.71 | 16.04K | 890.40 |
| Interest Expense | 145.15K | 100.87K | 68.13K | 233.70K | 819.71K | 1.07M | 890.40K |
| Depreciation & Amortization | 11.41K | 11.41K | 10.05K | 2.30M | 4.20M | 3.45M | 5.77M |
| EBITDA | -11.80M | -15.47M | -11.85M | 0.00 | -430.40K | -613.20K | -5.77M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -11.81M | -15.48M | -11.86M | -2.30M | -4.20M | -3.45M | -5.77M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -364.97K | -1.01M | -85.46K | -562.07K | -1.25M | -1.70M | -890.40K |
| Income Before Tax | -12.17M | -16.50M | -11.95M | -2.86M | -5.45M | -5.15M | -6.66M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 2.00 | -226.51K | -2.30K | -4.20K | 1.70M | -5.77K |
| Net Income | -12.17M | -16.50M | -11.95M | -2.86M | -5.45M | -5.15M | -6.66M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.32 | -0.84 | -0.81 | -0.59 | -0.49 | -0.44 | -0.57 |
| EPS Diluted | -0.32 | -0.84 | -0.81 | -0.59 | -0.49 | -0.44 | -0.57 |
| Weighted Avg Shares Out | 38.18M | 19.68M | 14.75M | 4.82M | 11.14M | 11.78M | 11.78M |
| Weighted Avg Shares Out (Dil) | 38.18M | 19.68M | 14.75M | 4.82M | 11.14M | 11.78M | 11.78M |
NLS Pharmaceutics to Present at the 35th Annual Roth Conference
ZURICH, SWITZERLAND / ACCESSWIRE / March 1, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous...
NLS Pharmaceutics Announces an R&D Update Webcast to Review the Company's Growing Portfolio of Pre-Clinical Compounds
Management to Discuss Pipeline Goals and Development Strategies across four Preclinical and 2 Clinical Programs across Multiple Central Nervous System (CNS) Disorders NLS to Webcast its R&D Day Event Tuesday, January 31 at 10:00am EST ZURICH, SWITZERLAND / ACCESSWIRE /...
NLS Pharmaceutics to Participate in Upcoming Investor Conferences
ZURICH, SWITZERLAND / ACCESSWIRE / January 11, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous...
3 Penny Stocks To Watch If You're Playing The “Stock Market Game”
Hot Penny Stocks To Watch Right Now. The post 3 Penny Stocks To Watch If You're Playing The “Stock Market Game” appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
4 Hot Penny Stocks To Watch This Week
Penny stocks to add to your watch list this week. The post 4 Hot Penny Stocks To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
What Know About Buying Penny Stocks on July 22nd
Here's what you need to know about buying penny stocks on July 22nd The post What Know About Buying Penny Stocks on July 22nd appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
NLS Pharma Shares Fall After Mazindol ER Interim Data Shows 39% Improvement On Sleepiness Scale
NLS Pharmaceutics Ltd (NASDAQ: NLSP) has announced interim topline data from its Phase 2a trial of its lead product candidate, Quilience (Mazindol ER), in narcolepsy. For excessive daytime sleepiness (EDS), the trial's primary endpoint, patients on Mazindol ER exhibited a.
Why Are NLS Pharmaceutics Shares Trading Higher During Premarket Monday?
NLS Pharmaceutics Ltd NLSP shares are trading higher after the Company announced to present interim topline data from its Phase 2a trial evaluating its lead product candidate, Quilience (Mazindol ER), for narcolepsy at World Sleep Congress 2022. Get the Inside Access...
NLS Pharmaceutics to Present Interim Top-Line Data for Quilience(R) (Mazindol ER) in Patients with Narcolepsy at the World Sleep Congress in March 2022
Phase 2a trial meets enrollment target for interim analysis and is now more than 50% enrolled 21 clinical sites in the United States actively enrolling patients Nearly 90% of patients completing the trial have opted into the Open Label Extension...
3 Penny Stocks to Watch in the Second Week of January
Here are three penny stocks to add to your watchlist for next week The post 3 Penny Stocks to Watch in the Second Week of January appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Source: https://incomestatements.info
Category: Stock Reports